Compare GLU & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | SGMO |
|---|---|---|
| Founded | 2004 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 141.2M |
| IPO Year | N/A | 2000 |
| Metric | GLU | SGMO |
|---|---|---|
| Price | $19.12 | $0.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 8.1K | ★ 90.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | ★ 10.20 |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $36,567,000.00 |
| Revenue This Year | N/A | $107.15 |
| Revenue Next Year | N/A | $76.44 |
| P/E Ratio | $30.69 | ★ N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $16.60 | $0.12 |
| 52 Week High | $21.69 | $0.77 |
| Indicator | GLU | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 37.98 |
| Support Level | $18.91 | N/A |
| Resistance Level | $20.17 | $0.55 |
| Average True Range (ATR) | 0.33 | 0.03 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 62.20 | 34.48 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.